NCT03871855 2023-06-05A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid TumorsJiangsu HengRui Medicine Co., Ltd.Phase 1 Terminated8 enrolled